Literature DB >> 773500

Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial.

H Berry, S P Liyanage, R A Durance, C G Barnes, L A Berger, S Evans.   

Abstract

Sixty-five patients, 33 receiving azathioprine and 32 receiving penicillamine, took part in a one-year, single-blind external-observer trial designed to compare the efficacy and toxicity of these two drugs in the treatment of rheumatoid arthritis. By six months there was a significantly greater rise in haemoglobin and fall in erythrocyte sedimentation rate among those receiving penicillamine, and by one year this difference remained only in the increase in haemoglobin levels. Fifteen patients, 10 on azathioprine and 5 on penicillamine, had to stop treatment because of side effects; 90 single side effects occurred, 48 in those on penicillamine and 42 in those on azathioprine. After one year both drugs were similar in efficacy and toxicity, but longer-term trials are needed. Both drugs were effective.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773500      PMCID: PMC1639855          DOI: 10.1136/bmj.1.6017.1052

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  2 in total

1.  Controlled trial of D(-)penicillamine in severe rheumatoid arthritis.

Authors: 
Journal:  Lancet       Date:  1973-02-10       Impact factor: 79.321

2.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07
  2 in total
  14 in total

1.  Penicillamine treatment of rheumatoid arthritis with a single daily dose of 250 mg.

Authors:  I A Jaffe
Journal:  Proc R Soc Med       Date:  1977

2.  Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up.

Authors:  A A Drosos; D Psychos; A P Andonopoulos; S Stefanaki-Nikou; E B Tsianos; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Alclofenac and D-penicillamine. Comparative trial in rheumatoid arthritis.

Authors:  H Berry; L Fernandes; A W Ford-Hutchinson; S J Evans; E B Hamilton
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

4.  Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.

Authors:  T Matsubara; R Saura; K Hirohata; M Ziff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

5.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

6.  Serum biochemistry in relation to the action of azathioprine in rheumatoid arthritis.

Authors:  J S Dixon; H A Bird; N G Sitton; M E Pickup; P A Leatham; V Wright
Journal:  Agents Actions       Date:  1983-06

Review 7.  Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection.

Authors:  C G Jackson; H J Williams
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 8.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

9.  Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes.

Authors:  P E Lipsky
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

10.  Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4.

Authors:  P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.